By
ZipLine Medical said today it closed a $12 million Series E round of financing, with funds slated to support commercialization of its Zip surgical skin closure portfolio and product development.
The round was led by newly invested growth equity fund HighCape Partners, and was joined by existing investor MVM Life Science Partners. As part of the financing round, HighCape Parnters operating partner Dean Tozer will join the company’s medical board of directors.
“ZipLine Medical has introduced a revolution in surgery – advanced wound closure that addresses inherent limitations with traditional, antiquated methods. The ZipLine team is developing and marketing disruptive products that minimize risk, improve clinical outcomes and address the constant pursuit of cost-effective healthcare,” = Tozer said in a prepared statement.
“We are excited to help propel the company to the next level of growth and commercial success,” HighCape Partners founder Matt Zuga said in a prepared release.
